Objectives: There is an increasing body of evidence suggesting a direct pathophysiological role of anti-citrullinated peptide antibodies (ACPA) in rheumatoid arthritis (RA), and immunological remission could be a target for treatment. However, data related to the ability of biologics to reduce ACPA titres are contradictory.We aimed to evaluate the changes in ACPA titres after treatment with different biologics in patients with RA.
Methods: As a first step, a systematic review of the literature available on 3 biologics (TNFi, abatacept and rituximab) and ACPA in patients with RA was performed in Pubmed and Cochrane. As a second step, a retrospective study was performed: all RA patients treated with the 3 above-mentioned biologics were identified. To be included in the analysis, patients had to have at least two titres of ACPA (one before and one after biologic treatment) available. ACPA titres were compared before and after treatment in each of the treatment groups.
Results: As a result of the literature review, 24 articles were retained confirming that the data on change in ACPA under biologics is contradictory, particularly for abatacept and TNFi. 144 RA patients (79.3% female, mean age: 56 years) were included in the retrospective analysis: 59 patients had received rituximab, 31 abatacept, 55 TNFi. ACPA titres decreased significantly with rituximab but not with abatacept nor TNFi. Modelling of ACPA titres over follow-up confirmed the significant decrease of ACPA over time rituximab.
Conclusions: In this real-life study, ACPA titres only significantly decreased after treatment with rituximab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.55563/clinexprheumatol/1h6h71 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Likelihood Ratios of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody in Clinical Diagnosis of Rheumatoid Arthritis by Two Available Platforms.
Diagnostics (Basel)
January 2025
Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.
: Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases, characterized by an articular and extra-articular involvement, where autoantibodies, such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPAs), are important biomarkers for the diagnosis. Autoantibody determination can be carried out using different assays. However, the results obtained are usually expressed in arbitrary units that are not comparable.
View Article and Find Full Text PDFBiomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases.
RMD Open
November 2024
Transplantation & Immunogenetics Service, Australian Red Cross Blood Service New South Wales and Australian Capital Territory, Alexandria, New South Wales, Australia.
Objectives: The determinants of rheumatoid arthritis (RA) severity and excess cardiovascular disease (CVD) are incompletely understood. Biomechanical factors are known to influence RA severity. Articular stiffness correlates with arterial and skin stiffness.
View Article and Find Full Text PDFA Clinical Evaluation of the Role of Autoimmunity in the Relation Between Erosions and Bone Mineral Density in Rheumatoid Arthritis.
Biomedicines
October 2024
Department of Rheumatology, Nancy University Hospital, F-54000 Nancy, France.
Article Synopsis
- The study examines the link between bone erosions and bone mineral density (BMD) in rheumatoid arthritis (RA) patients, suggesting a common pathway.
- A total of 149 RA patients were analyzed, revealing that higher erosion scores correlated with lower BMD levels, particularly in the hip region.
- Although autoantibodies like anti-citrullinated peptide antibodies (ACPAs) were associated with increased erosion and lower BMD, the relationship between erosion and BMD isn’t solely driven by these autoimmune factors, indicating the need for osteoporosis screening in these patients.
Immunophenotypic Landscape of synovial tissue in rheumatoid arthritis: Insights from ACPA status.
Heliyon
July 2024
Department of Rheumatology and Immunology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China.
Objective: To examine the clinical features and synovial pathologies in rheumatoid arthritis (RA) patients across varying titers of circulating anti-citrullinated protein antibodies (ACPA).
Methodology: We devised a negative pressure suction and rebound synovial biopsy tool to enhance the yield of synovial biopsies, noted for its ease and safety of use. This research involved a retrospective examination of 60 active RA patients who underwent synovial biopsies with this tool from June to November 2013 at our institution.
Differences in referral path, clinical and radiographic outcomes between seronegative and seropositive rheumatoid arthritis Mexican Mestizo patients: A cohort study.
PLoS One
June 2024
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán (INCMyN-SZ), Mexico City, Mexico.
Background: The study compared the referral path, the first two-year clinical outcomes, and the first five-year radiographic outcomes between seronegative patients (SNPs) from a recent-onset rheumatoid arthritis dynamic cohort initiated in 2004 and seropositive patients (SPPs). Predictors of incidental erosive disease were investigated.
Patients And Methods: Up to March 2023, one independent observer reviewed the charts from 188 patients with at least two years of clinical assessments and up to five years of annual radiographic assessments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!